Drug Profile
SKP 1032
Alternative Names: SKP-1032Latest Information Update: 18 Jan 2011
Price :
$50
*
At a glance
- Originator SkyePharma AG
- Class Analgesics; Anti-inflammatories
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- Available For Licensing Yes - Inflammation; Pain
Highest Development Phases
- No development reported Inflammation; Pain
Most Recent Events
- 18 Jan 2011 No development reported - Phase-I for Inflammation in United Kingdom (PO)
- 18 Jan 2011 No development reported - Phase-I for Pain in United Kingdom (PO)
- 29 Jun 2007 SKP 1032 is available for licensing (http:www.skyepharma.com)